Showing 1 - 7 results of 7 for search 'Do-Youn Oh', query time: 0.02s Refine Results
  1. 1
    Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

    Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer by Makoto Ueno, Masafumi Ikeda, Do-Youn Oh, Masatoshi Kudo, Christoph Helwig, Changhoon Yoo, Hye Jin Choi, Shunsuke Kondo, Li-Tzong Chen, Motonobu Osada, Isabelle Dussault

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Prognostic value of the mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX

    Prognostic value of the mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX by Min Kyu Kim, In Rae Cho, Yooeun Kim, Jin Ho Choi, Kwangrok Jung, Jaihwan Kim, Sheehyun Kim, Hongseok Yun, Jeesun Yoon, Do-Youn Oh, Kwangsoo Kim, Sang Hyub Lee

    Published 2024-10-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Comprehensive molecular analysis of 26 newly established human pancreatic ductal adenocarcinoma cell lines reveals two clusters with variating drug sensitivities

    Comprehensive molecular analysis of 26 newly established human pancreatic ductal adenocarcinoma cell lines reveals two clusters with variating drug sensitivities by Ju Eun Maeng, Jae-Hyeon Kim, Soon-Chan Kim, Won-Gun Yun, Wooil Kwon, Youngmin Han, Do-Youn Oh, Sang Hyub Lee, Jin-Young Jang, Ja-Lok Ku

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma

    Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma by Su In Lee, Ah-Rong Nam, Kyoung-Seok Oh, Jae-Min Kim, Ju-Hee Bang, Yoojin Jeong, Sea Young Choo, Hyo Jung Kim, Jeesun Yoon, Tae-Yong Kim, Do-Youn Oh

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer.

    Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. by Hye Rim Ha, Do-Youn Oh, Tae-Yong Kim, KyoungBun Lee, Kyubo Kim, Kyung-Hun Lee, Sae-Won Han, Eui Kyu Chie, Jin-Young Jang, Seock-Ah Im, Tae-You Kim, Sun-Whe Kim, Yung-Jue Bang

    Published 2016-01-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial

    Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial by Funda Meric-Bernstam, Sun Young Rha, Erika Hamilton, Yoon-Koo Kang, Diana L. Hanna, Syma Iqbal, Keun-Wook Lee, Jeeyun Lee, Muralidhar Beeram, Do-Youn Oh, Jorge Chaves, Rachel A. Goodwin, Jaffer A. Ajani, Lin Yang, Rajen Oza, Elena Elimova

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

    DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B by Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, In-Ho Kim, Do-Youn Oh, Hope Uronis, Sun Jin Sym, Mohamad Sonbol, Khaldoun Almhanna, Mohamedtaki A. Tejani, Beodeul Kang, Michael H. Kagey, Melissa Stilian, Calvin Jia, Cynthia A. Sirard, Jaffer A. Ajani, Samuel J. Klempner

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: